FDA Clearance Tracker · P930038-S052
ANGIO-SEAL VASCULAR CLOSURE DEVICE
Last checked: Nov 20, 2026Latest source record: Sep 26, 2008 (this decision)Source: openFDAMethods & limitations
Decided
Sep 26, 2008
Approved
Time to decision
273 days
Received Dec 28, 2007. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P930038-S052
- Device name
- ANGIO-SEAL VASCULAR CLOSURE DEVICE
- Applicant
- Terumo Medical Corporation
- Applicant location
- Elkton, MD
- Received
- Dec 28, 2007
- Decided
- Sep 26, 2008
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P930038
Device type
- Device type
- Device, hemostasis, vascular (MGB)
- Device class
- Class III
- Specialty
- Cardiology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR USE OF THE ANGIO-SEAL VASCULAR CLOSURE DEVICE IN CLOSURE OF FEMORAL VENOUS PUNCTURE SITES AND FOR THE REMOVAL OF THE PRECAUTION STATEMENT RELATING TO THE USE OF THE ANTICOAGULANT WARFARIN. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME ANGIO-SEAL VASCULAR CLOSURE DEVICE AND IS INDICATED FOR USE IN CLOSING AND IN REDUCING TIME TO HEMOSTASIS AT THE FEMORAL ARTERIAL AND FEMORAL VENOUS PUNCTURE SITE IN PATIENTS WHO HAVE UNDERGONE DIAGNOSTIC ANGIOGRAPHY OR PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY (PTCA) PROCEDURES USING AN 8 FRENCH OR SMALLER PROCEDURAL SHEATH.
Source documents
Other decisions for Terumo Medical Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- MISAGO(TM) RX Self-expanding Peripheral StentPMA supplement
P140002-S032 · Decided Jul 16, 2026 · 199 days after receipt · Panel Track
Device type: STENT, ILIAC (NIO) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.